노르웨이 -
노르웨이어 -
Statens legemiddelverk
sehcat tm 370 kbq
ge healthcare buchler gmbh & co. kg - tauroselkolsyre - kapsel, hard - 370 kbq
노르웨이 -
노르웨이어 -
Statens legemiddelverk
sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq
노르웨이 -
노르웨이어 -
Statens legemiddelverk
sodium iodide [131i] injection ge healthcare 925 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 925 mbq/ ml
노르웨이 -
노르웨이어 -
Statens legemiddelverk
sodium iodide [131i] injection ge healthcare 74 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 74 mbq/ ml
유럽 연합 -
노르웨이어 -
EMA (European Medicines Agency)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
유럽 연합 -
노르웨이어 -
EMA (European Medicines Agency)
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
노르웨이 -
노르웨이어 -
Statens legemiddelverk
audalis 60 mg
medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 60 mg
노르웨이 -
노르웨이어 -
Statens legemiddelverk
audalis 10 mg
medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 10 mg
노르웨이 -
노르웨이어 -
Statens legemiddelverk
audalis 18 mg
medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 18 mg
노르웨이 -
노르웨이어 -
Statens legemiddelverk
audalis 25 mg
medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 25 mg